| Stereochemistry | RACEMIC |
| Molecular Formula | C12H17NO3 |
| Molecular Weight | 223.2683 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CNC1CCC1)C2=CC(O)=C(O)C=C2
InChI
InChIKey=OVTZNVCECJYMDW-UHFFFAOYSA-N
InChI=1S/C12H17NO3/c14-10-5-4-8(6-11(10)15)12(16)7-13-9-2-1-3-9/h4-6,9,12-16H,1-3,7H2
| Molecular Formula | C12H17NO3 |
| Molecular Weight | 223.2683 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Norbudrine (KWD2109) is a sympathomimetic drug. It is an active bronchospasmolytic agent. KWD2109 shows an in vitro bronchospasmolytic acitivity which is about 14 times better than that of KWD2025. In the in vivo tests or guinea pig bronchospasmolytic activity KWD2109 has an effect which is about 3 times that of KWD2025 after intraperitoneal and oral administration
Approval Year
Sample Use Guides
The compound Norbudrine (KWD2109) and KWD2025 have been compared in preventing bronchospasm induced by histamine aerosol in guinea pigs.
The drug was injected intraperitoneally 15 minutes or administered orally 30 minutes before histamine treatment. To study the duration of the effect, 2 mg/kg was administered orally to intact guinea pigs at different time intervals before the histamine treatment.
Route of Administration:
Other
